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delivery of AAV2-AADC to midbrain dopaminergic
neurons
Toni S. Pearson 1,2,12, Nalin Gupta 1,12, Waldy San Sebastian1, Jill Imamura-Ching1, Amy Viehoever 3,
Ana Grijalvo-Perez3, Alex J. Fay3, Neha Seth4, Shannon M. Lundy5, Youngho Seo 6, Miguel Pampaloni6,
Keith Hyland7, Erin Smith8, Gardenia de Oliveira Barbosa9, Jill C. Heathcock9, Amy Minnema10, Russell Lonser10,
J. Bradley Elder10, Jeffrey Leonard10,11, Paul Larson1 & Krystof S. Bankiewicz1,10✉
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare genetic disorder char-
acterized by deficient synthesis of dopamine and serotonin. It presents in early infancy, and
causes severe developmental disability and lifelong motor, behavioral, and autonomic
symptoms including oculogyric crises (OGC), sleep disorder, and mood disturbance. We
investigated the safety and efficacy of delivery of a viral vector expressing AADC (AAV2-
hAADC) to the midbrain in children with AADC deficiency (ClinicalTrials.gov Identifier
NCT02852213). Seven (7) children, aged 4–9 years underwent convection-enhanced delivery
(CED) of AAV2-hAADC to the bilateral substantia nigra (SN) and ventral tegmental area
(VTA) (total infusion volume: 80 µL per hemisphere) in 2 dose cohorts: 1.3 × 1011 vg (n= 3),
and 4.2 × 1011 vg (n= 4). Primary aims were to demonstrate the safety of the procedure and
document biomarker evidence of restoration of brain AADC activity. Secondary aims were to
assess clinical improvement in symptoms and motor function. Direct bilateral infusion of
AAV2-hAADC was safe, well-tolerated and achieved target coverage of 98% and 70% of the
SN and VTA, respectively. Dopamine metabolism was increased in all subjects and FDOPA
uptake was enhanced within the midbrain and the striatum. OGC resolved completely in 6 of
7 subjects by Month 3 post-surgery. Twelve (12) months after surgery, 6/7 subjects
gained normal head control and 4/7 could sit independently. At 18 months, 2 subjects could
walk with 2-hand support. Both the primary and secondary endpoints of the study were met.
Midbrain gene delivery in children with AADC deficiency is feasible and safe, and leads to
clinical improvements in symptoms and motor function.
https://doi.org/10.1038/s41467-021-24524-8 OPEN
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Aromatic L-amino acid decarboxylase (AADC) deficiency isa rare autosomal recessive neurodevelopmental disorderthat typically presents in infancy, and is characterized
biochemically by deficiency of the catecholamines (dopamine,
epinephrine, and norepinephrine) and serotonin1. Approximately
135 patients with this condition have been reported in the lit-
erature worldwide, though the true incidence is unknown2. The
AADC enzyme catalyzes the synthesis of dopamine and serotonin
from their respective precursors. Children with AADC deficiency
cannot metabolize levodopa to dopamine, and for this reason,
patients typically do not respond to treatment with exogenous
levodopa. In addition, they derive little or no benefit from other
medical therapies2,3. The majority of patients experience severe
long-term physical and intellectual disability, and are at risk of
premature death from complications related to the disease.
AADC deficiency causes a variety of motor, autonomic, and
behavioral symptoms. The motor symptoms include hypokinesia,
hypotonia, dystonia, and oculogyric crises (OGC). OGC are one
of the cardinal features of the disease, and are characterized by
episodes of intermittent or sustained tonic vertical (usually
upward), horizontal, or convergent deviation of the eyes, some-
times accompanied by dystonia or other involuntary movements
of the face and body. Episodes typically last for hours and occur
several times per week4. Catecholamine and serotonin deficiency
also cause non-motor symptoms such as emotional lability, sleep
disturbance, and excessive sweating. Moderate to severe motor
and intellectual disability is present in at least 70% of the patients
described to date2,4,5.
A number of surgical strategies have been used to treat adult
patients with Parkinson’s disease (PD), a neurodegenerative dis-
order in which brain AADC activity is progressively lost due to
disease progression or cell death. These include placement of deep
brain stimulation electrodes6, cell transplants7, and gene therapy8.
Most clinical trials evaluating the efficacy of gene therapy for PD
have utilized an adeno-associated virus type 2 (AAV2), encoding
a neurotrophic factor9,10 or the DDC gene (hAADC), delivered by
a direct surgical procedure to the putamen11,12. The rationale for
selection of the putamen as the anatomic target in PD for DDC
gene therapy is that transduction of the post-synaptic cells that
express dopamine receptors in the putamen may provide suffi-
cient AADC activity to cause an increase in local metabolism of
exogenous levodopa (i.e., dopaminergic medication) and a sub-
sequent increase in striatal levels of dopamine13.
In contrast to previous studies in PD, we hypothesized that
patients with AADC deficiency would benefit from AAV2-
hAADC delivery to two specific regions of the midbrain: the
substantia nigra pars compacta (SNc) and the ventral tegmental
area (VTA). The rationale for the selection of the midbrain target
as opposed to the putamen is that dopaminergic neurons in the
midbrain and their axonal projections are structurally intact in
children with AADC deficiency14. Furthermore, the mood and
autonomic symptoms that accompany severe motor impairment
may be attributable in part to dopamine deficiency beyond the
nigrostriatal system, and thus would not be treated by putaminal
transduction.
AAV2-hAADC gene delivery to the putamen for children with
AADC deficiency has been investigated in Taiwan15,16 and
Japan17. In all, 14 subjects in Taiwan (ages 1.7–8.4 years, total
dose 1.5 × 1011 vg in 160 µL15 or 1.81 × 1011 vg in 160 µL16) and
6 subjects in Japan (ages 4–19, total dose 2 × 1011 vg in 200 µL17)
were treated with bilateral intraputaminal infusion of AAV2-
hAADC. The authors reported some clinical improvements, but
OGC persisted in all subjects. Only 2 of the 12 patients in the
latter two studies who had been followed for at least 2 years
gained the ability to sit independently16,17.
By delivering AAV2-hAADC to the SNc and VTA, our goal
was to increase AADC enzyme activity in midbrain dopaminergic
neurons, thereby rescuing dopamine biosynthesis and dopami-
nergic neurotransmission in nigrostriatal, mesolimbic, and
mesocortical pathways. Midbrain delivery also takes advantage of
anterograde axonal transport of AAV2 from these regions to
deliver AAV2-hAADC to neuroanatomically appropriate brain
regions like the striatum18,19. To maximize safety and targeting
accuracy of the gene vector in this trial we developed and utilized
a MR-guided gene delivery platform20–24. The primary aims of
this trial were to demonstrate the safety of the procedure and
detect biomarker evidence of increased brain AADC activity.
Secondary aims were to evaluate clinical improvements in OGC
and motor function after gene delivery.
The therapeutic approach described in this report has the
potential to improve disease-related symptoms and motor func-
tion in patients with AADC deficiency. The success of this general
strategy provides confirmation of targeted gene therapy as a tool
to effectively treat other genetic disorders of the central nervous
system (CNS). In particular, the techniques described in this
study validate the use of efficient viral vectors, brain imaging, and
Table 1 Baseline demographic and clinical characteristics of the 7 subjects.
Characteristic Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7
Age (y), sex 9.0, F 8.0, F 5.9, M 5.1, M 6.7, F 6.2, F 4.5, M
Motor development
Head control No Partial No No Partial No No
Reach/grasp No No No No Yes No No
Sit independently No No No No No No No
Symptoms
OGC ++ ++ ++ ++ ++ ++ ++
Irritability ++ + + ++ + + +
Insomnia ++ ++ ++ + - ++ +
DDC genotypea c.714+4A > T; c.714+4A > T; c.714+4A > T; c.19C > T
p. (Arg7X);











c.714+4A > T c.1217T > A
p.(Leu406Gln)
Follow-up duration 38 months 34 months 30 months 22 months 20 months 7 months 7 monthsb
M male, F female, OGC oculogyric crises, ++ severe, + mild or moderate, - absent.
aDDC reference sequence: NM_001082971.1(DDC).
bSubject 7 died 7 months after the procedure.
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optimized delivery tools as an overall framework for other clinical
applications.
Results
Subjects. Seven (7) subjects (4 female/3 male, age range 4–9 years,
Table 1) were treated with viral gene therapy according to the
study protocol (see Online Methods section). Subjects were
enrolled sequentially into two dose groups: 3 subjects in Group 1
(8.3 × 1011 vg/mL, treated January–September 2017) followed by
4 subjects in Group 2 (2.6 × 1012 vg/mL, i.e. a 3-fold increase in
vector concentration, treated May 2018–August 2019). The total
infusate volume was 160 μL of vector for each subject. The
duration of post-procedure follow-up is 24–36 months for the
3 subjects in Cohort 1, and 6–18 months for the 4 subjects in
Cohort 2 (Table 1). The study was reviewed and approved by the
Institutional Review Boards at the University of California San
Francisco (Protocol No. 15-17756, approved on 24 June 2016)
and The Ohio State University Wexner Medical Center (Protocol
No. 2018H0269, approved on 29 November 2019).
Target distribution of the vector. Using real-time MR imaging,
we were able to confirm accurate placement of the infusion
catheter at each target (bilateral SNc and VTA) for all 7 subjects
(Fig. 1A–C, see Online Methods for details). The pattern of dis-
tribution followed a roughly oval shape surrounding the catheter
tip. In 1 subject, at one target, there was perivascular spread of the
contrast agent along a brainstem vessel. Our previous studies
have demonstrated that the distribution of the gadoteridol closely
matches distribution of the infused AAV2 vector19,22,23. Based on
anatomic boundaries identified on the pre-procedural MR scans,
infusion of 50 µL into the SN resulted in mean coverage (mean ±
SD) of approximately 174 ± 49 mm3 with one suboptimal infu-
sion due to leakage along the perivascular space which was
excluded from analysis (n= 13). Infusion of 30 µL into VTA
resulted in coverage of 107 ± 23 mm3 (n= 14), (Fig. 1B). The
volume of distribution was 3 times the volume of infusion in the
SN, and 3.4 times the volume of infusion in the VTA.
Evidence of increased brain AADC activity after gene delivery.
We performed 6-[18F]-fluoro-L-DOPA (FDOPA) PET imaging at
Baseline, Month 3, and Month 24 to look for evidence of a change
in brain AADC activity after gene delivery. Integrity of the
nigrostriatal pathway as described by Lee et al.14 was confirmed by
imaging of the dopamine transporter (DaTscan™) in all subjects at
Screening (Fig. 1D). Pre-operative FDOPA PET demonstrated no
evidence of FDOPA uptake in the striatum or other brain regions
(Fig. 1E, F), consistent with absent AADC activity. Post-operative
images at both Month 3 and Month 24 demonstrated increased
FDOPA uptake in the midbrain (site of gene delivery, Fig. 1G, and
Supplementary Fig. 1A) and also in brain regions that receive
dopaminergic projections from the midbrain. A diffuse increase of
FDOPA signal was detected in both putamen and caudate nucleus
(striatum) (Fig. 1H and Supplementary Fig. 1B). Detection of
increased FDOPA uptake in the striatum is consistent with our
hypothesis that the AAV2-hAADC vector and AADC protein both
undergo anterograde axonal transport via the intact nigrostriatal
pathway into nigrostriatal terminals with accompanying enzymatic
conversion of levodopa into dopamine.
Neurotransmitter metabolites were assayed in CSF on
2 separate occasions before the procedure (at screening and on
the day of surgery), and four times after the procedure at months
3, 6, 12, and 24. (Fig. 2 and Table 2). At baseline, concentrations
of the dopamine metabolite, homovanillic acid (HVA), were
Fig. 1 MR-guided delivery of AAV2-hAADC into the midbrain, baseline DaTscan and changes in FDOPA PET biomarker after gene delivery. Coronal
(A) and axial (C) MR images at the conclusion of the vector infusions into SN and VTA regions (white arrows). Bright signal corresponds to gadoteridol
admixed with AAV2-hAADC. Infusions are performed sequentially while imaging, starting with right SN. Please, note accurate targeting and coverage in
respective anatomical regions. B Coverage (volume of distribution, Vd) of all infusions performed into the SN and VTA in 7 subjects (n= 2 independent
infusion sites (left and right) examined per participant (n= 7) for each target structure (SNc and VTA), for a total of n= 14 independent infusions per
target structure). SN infusion (50 µL) achieved coverage of ~160 ± 60mm3 (mean ± SD, n= 14 infusions (two infusions per participant)) with one
suboptimal infusion due to leakage along the perivascular space. VTA infusion (30 µL) resulted in coverage of 103 ± 22mm3. Coverage volume of
gadoteridol (Vd) suggests almost 80% anatomical coverage of both SN and VTA in all subjects (except single SN in one patient). D DaTscan imaging of
the striatum at baseline confirmed a normal pattern of dopaminergic innervation in all study subjects, indicative of preserved nigrostriatal pathway. E, F
Baseline FDOPA imaging of the midbrain regions (SN and VTA, black arrows in E) and nigrostriatal projection (caudate nucleus and putamen, dotted line in
F). Lack of signal in both regions represents impaired conversion of FDOPA to F-dopamine due to absent AADC activity. G, H Increased FDOPA PET uptake
3 months after AAV2-hAADC administration in the midbrain and striatum, respectively. Images for Subject 4 are shown as representative of the group; see
Supplementary Fig. S1 for images for each individual subject. Source data are provided as a Source Data file.
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<17% of the lower limit of normal in all subjects (Fig. 2a and
Table 2). HVA concentration increased significantly 3 months
after gene delivery compared to the mean of the two baseline
measurements (p= 0.0078, one-tailed Wilcoxon signed-rank test,
n= 7). This increase was sustained at Month 6 (p= 0.0078, n=
7) and Month 12 (p= 0.0313, n= 5) (Fig. 2a). CSF 5-
hydroxyindolacetic acid (5-HIAA) concentration did not change
after gene delivery (Fig. 2b and Table 2), consistent with
expectations since serotonergic nuclei were not targeted in this
procedure. 3-O-methyldopa (3-OMD), an alternate metabolite of
levodopa, was elevated in all assays and did not consistently
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Fig. 2 CSF Neurotransmitter metabolites. Concentrations of CSF metabolites measured at 2 separate baseline (BL) timepoints, Month 3, Month 6, and
Month 12, in individual subjects in Cohort 1 (low-dose, black markers); and Cohort 2 (high-dose, white markers) and summarized at each timepoint as the
group median (bars). A Homovanillic acid (HVA), the dopamine metabolite, was significantly higher at each post-operative timepoint compared to the
baseline mean (inverted bracket; (*p= 0.0078 at Months 3 and 6, p= 0.0313 at Month 12, one-tailed Wilcoxon signed-rank test). Lower limit of normal
range: 218 nmol/L (dotted line). B 5-hydroxyindoleacetic acid (5-HIAA), the serotonin metabolite, did not change after gene delivery. Lower limit of normal
range: 66 nmol/L (dotted line). C 3-O-methyldopa (3-OMD) was elevated in all subjects at all timepoints. Normal: <100 nmol/L (dotted line). Source data
can be found in Table 2.
Table 2 CSF neurotransmitter metabolites.
Metabolite (normal range) Baseline Month 3 Month 6 Month 12 Month 24
BL1 BL2
HVA (218–852 nmol/L)
Subject 1 <5 15 49 59 52 12
Subject 2 18 10 66 56 52 73
Subject 3 12 14 71 89 103 137
Subject 4 10a 7 12 75 57 –
Subject 5 12 11 76 70 59 –
Subject 6 5 8 134 138 – –
Subject 7 37 38 172 146 – –
5-HIAA (66–338 nmol/L)
Subject 1 10 7 <5 <5 7 <5
Subject 2 <5 <5 <5 <5 <5 8
Subject 3 5 <5 <5 <5 7 24
Subject 4 <5 <5 13 25 <5 –
Subject 5 21 <5 <5 8 <5 –
Subject 6 <5 5 12 6 – –
Subject 7 5 42 26 14 – –
3-OMD (<100 nmol/L)
Subject 1 605 600 504 549 875 443
Subject 2 719 556 489 410 368 460
Subject 3 378 358 443 413 303 432
Subject 4 2104a 578 517 426 441 –
Subject 5 343 529 379 632 625 –
Subject 6 429 411 446 325 – –
Subject 7 928 769 558 556 – –
HVA homovanillic acid, 5-HIAA 5-hydroxyindoleacetic acid, 3-OMD 3-O-methyldopa.
aSubject 4 was taking carbidopa-levodopa at the time of the first baseline lumbar puncture. The medication was tapered off prior to the day of surgery (2nd baseline lumbar puncture).
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Oculogyric crises improved in all subjects. Subjects’ caregivers
recorded a log of the duration and severity of each OGC observed
from 2 months before surgery through the 24-month follow-up
period. We summarized the average burden of OGC for each
month, using a score that represents the weekly duration (in
hours) weighted by the severity (grade 1–3) of episodes. For
example, 5 h per week of moderate episodes (grade 2: eye
deviation associated with involuntary facial movements) would be
represented by a score of 10, while 10 h per week of severe
symptoms (grade 3: whole body dystonia) would result in a score
of 30. All subjects experienced several hours per week of OGC at
baseline (OGC score range: 3.2–35).
After gene delivery, OGC ceased completely in 6/7 subjects.
Resolution occurred within 9–33 days of surgery for 5 subjects,
and within 90 days for 1 subject (Fig. 3a). This resolution was
sustained throughout the study follow-up period. In all, 1 subject
had residual episodes of significantly reduced severity compared
to baseline (Fig. 3a, insert) throughout 24 months of post-surgery
follow-up. The marked improvement in OGC provided clear
clinical evidence of increased brain AADC activity that began as
soon as 9 days after gene delivery.
Motor function and developmental milestones. Gross motor
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Fig. 3 Changes in Oculogyric Crises (OGC) and motor function after gene delivery. A The OGC score was calculated monthly, and represents the weekly
average of the duration of episodes (hours per week), weighted by severity (grade 1–3: 1=mild/eye deviation only; 2=moderate/eye deviation+ dystonia
or dyskinesia of the face and/or neck; 3= severe/dystonia or dyskinesia involving the trunk and/or limbs). By Month 3, OGCs completely resolved in 6/
7 subjects. Inset (black arrow): Subject 1 had residual episodes throughout the 24-month study period; the severity decreased after surgery (red arrow).
B Gross Motor Function Measure-88 (GMFM-88) scores for Cohorts 1 (red) and 2 (blue). Data are shown through Month 24 for Subjects 1–3, Month 18
for Subjects 4 and 5, and Month 6 for Subjects 6 and 7. Baseline GMFM scores for all subjects (circled) were ≤10, consistent with severe motor
impairment. Inset: changes in GMFM score between Baseline and Month 12. An increase of ≥7 points (dotted line, representing a clinically meaningful
positive change) was observed in 6/7 subjects by Month 12. Source data are provided as a Source Data file.
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(GMFM-88), a standardized instrument designed to assess
changes in motor function over time in children with motor
impairment due to cerebral palsy25. The total score, which ranges
from 0 to 100 percentage points, is derived as an unweighted
average of scores in five dimensions (lying and rolling; sitting;
crawling and kneeling; standing; and walking, running, and
jumping). The GMFM-88 was selected for this study as a tool to
assess motor function because it was developed to assess children
with motor impairment due to an insult to the developing brain
early in life (cerebral palsy), as occurs in AADC deficiency, and
because the GMFM can accurately test and measure changes in
children who have severe motor impairment.
The baseline GMFM-88 total scores of the 7 subjects ranged
from 0.4 to 10 points, consistent with severe impairments in gross
motor function (Fig. 3b). All subjects achieved recognizable gains
in motor function after the procedure, manifested by increased
tone and improvements in head and trunk control and purposeful
limb movements. The rate of improvement varied considerably
from 1 subject to another. An increase in GMFM score of at least
7 points, which is considered to be a clinically meaningful
improvement25, was observed in 4/7 subjects (57%) at Month 6,
and 6/7 subjects (86%) by Month 12 (median 9.7, range 3.8–19.1
points; Fig. 3b, inset). All 5 subjects (100%) who had at least
18 months of post-surgical follow-up (Subjects 1–5) had a >7-
point increase in GMFM-88 score at Month 18 (median 13.9,
range 8.6–23.7 points).
Motor function improvements after gene delivery were
accompanied by the attainment of developmental milestones.
Head control was attained by 4/7 subjects (57%) by Month 6, and
6/7 subjects (86%) by Month 12. Independent sitting was attained
by 4/7 subjects (57%) by Month 12 (Table 3 and Supplementary
Movies 1–3). At 12 months, 3/7 subjects (43%) could reach and
grasp (acquired after surgery in 2 of 3). Subjects 2 and 5 (baseline
ages 8 and 6 years, respectively) were additionally able to walk
with trunk support by Month 12, and to walk with 2-hand
support by Month 18. Two and a half (2.5) years after surgery,
Subject 2 started to take independent steps (Supplementary
Movie 1).
By Month 12, Subjects 2 and 5 were able to eat and drink by
mouth, and Subject 2 gained the ability to speak ~50 single words.
Subject 5 learned to communicate using an augmentative
communication device between 12 and 18 months after gene
delivery (Supplementary Movie 2). These functional gains
were reflected in raw score increases at 12 months across all
domains (Communication, Daily Living Skills, Socialization, and
Motor) of the Vineland Adaptive Behavior Scales 2nd edition for
Subjects 2 and 5 (Supplementary Table 1).
Improvement in non-motor symptoms of AADC deficiency. A
standard checklist of symptoms of AADC deficiency was
evaluated by study investigators, via parent interview, at baseline
and at each follow-up evaluation. Each symptom was rated as
‘major’ (frequent and/or severe), ‘minor’ (infrequent and/or
mild), or absent
Prior to gene delivery, all patients had a mood disturbance
characterized by frequent crying, irritability, or agitation. In 3/
7 subjects the mood symptoms were severe (Fig. 4a). Caregivers
periodically completed a 7-day sleep and behavior diary that
documented a transient increase in irritability for some subjects
1–3 months after surgery, followed by marked sustained
improvement in mood in all subjects (Fig. 4a, b and Supplemen-
tary Movie 3).
Five (5) of 7 subjects presented with severe sleep disturbance at
baseline, and parents subjectively reported an improvement in
their child’s sleep after surgery (Fig. 4c). It was difficult to
quantify this improvement based on data recorded in the
caregiver diary for most cases, but an overall trend towards an
increase in the number of hours of sleep per night can be
observed, and for Subject 2, the improvement in sleep quantity
was dramatic (Fig. 4d).
After gene delivery, parents also reported marked improve-
ment in sweating, feeding difficulties (such as vomiting), and
upper airway obstruction due to profuse oral secretions, nasal
congestion, and stridor (Fig. 4e–g). The improvement in feeding
tolerance in Subject 4 led to an increase in body weight from four
standard deviations below the mean for age at Baseline, to the 2nd
percentile at 22 months post-surgery. All subjects were receiving
enteral nutrition via gastrostomy at Baseline. Body weight at
Baseline for the other subjects ranged from the 6th–32nd
percentile, and remained stable over the course of follow-up.
Safety outcomes. All 7 subjects tolerated the surgical procedure
without any direct short-term or long-term adverse effects. In all,
1 subject was noted to have a focal depression of the calvarium at
a cranial pin site on a post-operative imaging study but this did
not affect the brain parenchyma and did not result in any other
consequences. There were no intracranial hemorrhages, strokes,
or infections related to the procedures. There were no recorded
serious adverse events related to the study intervention (Table 4).
Beginning 3–4 weeks after gene delivery, all subjects experi-
enced a transient worsening of irritability and sleep dysfunction
which improved within weeks and eventually reached a state that
was better than baseline (Fig. 4b, d). At 3–4 weeks, all subjects
also developed anticipated involuntary movements, or dyskinesia.
These motor and behavioral symptoms coincided with the initial
AAV-driven expression of AADC and subsequent abrupt increase
in dopamine synthesis. Dyskinesia peaked in severity between 1
and 3 months after surgery, and gradually improved over
subsequent months (Fig. 5). As dyskinesia emerged, dopaminer-
gic and anticholinergic medications were tapered in 6/7 subjects
Table 3 Developmental milestones after gene delivery.
Subject Follow-up duration
(months)













1 36 No No No No No No No No
2 33 ± Yes (2) No Yes (7) No Yes (10) No Yes (17)
3 30 No Yes (12) No Yes (21) No No No No
4 22 No Yes (7) No Yes (11) No Yes (10) No No
5 20 ± Yes (3) No Yes (7) Yes Yes No Yes (18)
6 7 No Yes (2.5) No Yes (7) No No No No
7 7 No Yes (4) No – No – No –
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Excessive sweating Feeding intolerance Upper airway obstruction
Fig. 4 Non-motor symptoms before and after gene delivery. A The percentage of subjects (n= 7) who, by caregiver report, experienced irritability at
baseline compared to the last available follow-up timepoint (Month 24 for Subjects 1–3, Month 18 for Subjects 4 and 5, and Month 6 for Subjects 6 and 7).
B The number of hours or irritability per day recorded in caregiver diaries increased slightly immediately after surgery, and then improved on average
(mean ± SE). C Prevalence and severity of insomnia before and after gene delivery by caregiver report. D The mean number of hours (±SE) of night-time
sleep recorded in caregiver diaries improved slightly across subjects after gene delivery. For Subject 2 (blue triangles), the improvement was dramatic. E–G
Prevalence and severity of other non-motor symptoms before and after gene delivery by caregiver report (see details in A, above). Major (black): frequent
and/or severe, with significant impact on comfort or function; Minor (gray): infrequent and/or mild. Source data are provided as a Source Data file.
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and 3/7 stopped all dopaminergic medications. No additional
medications were prescribed to treat the involuntary movements.
At Month 24, none of the 3 subjects in Cohort 1 had any residual
dyskinesia (Fig. 5).
One subject (Subject 7) died suddenly and unexpectedly at
home without any preceding illness, 7 months after surgery. The
subject had completed all study evaluations through Month 6,
when he appeared to be in good health, and demonstrated
improvements in symptoms and motor function. The cause of
death was unknown, and was judged to be most likely attributable
to the underlying primary disease.
Discussion
MR-guided convection-enhanced delivery (CED) of AAV2-
hAADC into the midbrain can be performed safely in children
with AADC deficiency. Children with AADC deficiency experi-
ence a combination of disabling motor and autonomic symptoms,
and severe motor and developmental disability. Minimal spon-
taneous improvement occurred in our study subjects prior to
enrollment. All 7 subjects exhibited measurable clinical
improvements in both symptoms and motor function following
gene delivery. OGC resolved completely in 6 of 7 subjects.
Although there was some variation in the rate and degree of
Table 4 Summary of adverse events and serious adverse events.
Adverse eventsa Serious adverse eventsb Fatality
Related to gene therapy
Skin irritation on cheeks due to dyskinesia 1 – –
Related to study procedures
Vomiting following administration of potassium iodide prior to DaTscan 1 – –
Post-operative anemia requiring transfusion 2 – –
Related to AADC deficiency
Sudden death of unknown cause – – 1
Hypoglycemia following sedation for study procedure 2 1 –
Non-specific
Viral respiratory tract infection – 5 –
Hematemesis associated with gastro-esophageal reflux – 1 –
Pneumonia – 2 –
Urinary tract infection – 1 –
Skin rash 2 – –
Eye infection/irritation 2 – –
Gastroenteritis 1 – –
Vomiting due to missed doses of anti-reflux medication 1 – –
Total 12 10 1
AADC aromatic L-amino acid decarboxylase deficiency.
AADC is a rare neurodevelopmental disorder. Here the authors describe a clinical trial of MR-guided delivery of AAV2-AADC for the treatment of AADC.
aAdverse events: classified as mild or moderate.
bSerious adverse events: classified as severe or medically significant, requiring or prolonging hospitalization.
































Fig. 5 Time course of dyskinesia after gene transfer. Dyskinesia score, adapted from the Abnormal Involuntary Movement Scale (AIMS). Involuntary
movements in each of 7 body regions were scored from 0 (none) to 4 (severe), for a maximum possible score of 28. A total score of 14 (dotted line) may
correspond with either mild generalized dyskinesia, or moderate-severe involuntary movements in a more focal distribution. Dyskinesia peaked in severity
between 1 and 3 months after surgery, and gradually improved thereafter. At Month 24, dyskinesia had resolved completely in all 3 subjects in Cohort 1.
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motor function improvement, 4 of the 5 subjects who had been
followed for at least 18 months after gene delivery gained the
ability to sit independently, and 2 of the 5 gained the ability to
walk with 2-hand support within that time period. Substantiating
these clinical observations, there was associated biomarker evi-
dence of increased brain AADC activity by measurement of HVA
in CSF and FDOPA PET imaging.
Direct infusion of AAV2-hAADC into the SNc and VTA is
technically feasible and was performed without surgical compli-
cations in this series of patients. Successful delivery of the DDC
gene therapy vector required identification of the anatomic tar-
gets, accurate placement of an intracranial catheter, and sub-
sequent confirmation of vector delivery. This approach was
accomplished through the use of real-time MR imaging in con-
junction with co-infusion of a MR contrast agent. Pre-operative
identification of the SNc and VTA using high-resolution MR
imaging allowed for planning of catheter trajectories designed to
prevent passage through eloquent regions. An MR-guided navi-
gation system allowed direct intra-operative confirmation of
catheter placement into the selected targets. Finally, vector infu-
sion was monitored with continuous MR imaging that confirmed
accurate and reproducible distribution of the infusate.
Infusion of AAV2-hAADC resulted in measurable changes in
clinical function and dopamine production suggesting that
restoration of AADC activity in physiological regions (midbrain)
can reverse the pathologic phenotype observed in primary AADC
deficiency. We observed dramatic improvements in symptoms,
including OGC, irritable mood, and sleep dysfunction. These
changes became apparent soon after gene delivery, typically
within the first 3 months. Caregivers reported that these changes,
particularly the resolution of OGC and improvements in sleep,
had a major positive impact on the child’s and family’s quality
of life.
Improvements in motor function unfolded over a longer time
course, and the rate of improvement varied considerably between
subjects. Greater improvement was not obviously associated with
either higher vector dose (Cohort 2) or with younger age in this
small group of subjects. All 7 subjects had severe motor impair-
ment at baseline, with severe hypotonia, minimal voluntary
movements, and lack of head control in most cases. After gene
delivery, the time to attain head control in 6 subjects ranged from
2 to 14 months, while the time to attain independent sitting
ranged from 7 to 21 months. GMFM-88 total scores improved by
more than 7 points in all subjects, and in 2 subjects (baseline ages
6 and 8 years) who gained the ability to walk with 2-hand sup-
port, eat and drink by mouth, and communicate either verbally or
with the aid of an augmentative communication device, the
observed change in score was >20 points. This magnitude of
motor function improvement in our subjects would not be
expected to occur in the natural course of AADC deficiency for
patients in this age range (4–9 years) who have severe motor
impairment. In a retrospective study of 63 patients (age range
6 months to 36 years), 11 subjects with a mild-moderate disease
phenotype were able to walk independently4. In those 11 subjects,
the potential for motor development was evident in early child-
hood, with all having attained the ability to sit independently by
age 4 years. In contrast, the subjects in our gene therapy trial had
absent head control at Baseline ages of 4 years and above, and
therefore would not have been expected to proceed to sit, stand,
or walk independently based upon what is known about the
typical course of developmental outcomes in this disease.
We propose that the broad range of clinical benefits we
observed are attributable to physiological restoration of dopamine
synthesis, storage, release, and reuptake in the pre-synaptic
terminal projections arising from midbrain dopaminergic neu-
rons. Dopaminergic neurons in SNc and VTA send highly
arborized projections into the striatum and nucleus accumbens26.
Thus, AAV2-AADC transduction of SNc and VTA neurons
would be expected to result in restoration of AADC activity in
widespread regions outside the midbrain, as demonstrated by the
distribution of changes in FDOPA PET uptake that we observed
in the caudate nucleus and the putamen in our subjects after gene
delivery.
Two groups in Taiwan and Japan have previously investigated
infusion of AAV2-AADC into the bilateral putamen.15–17. Con-
centrations of CSF HVA after surgery remained below 25% of the
normal range in the majority of subjects15,16. OGC were reported
to become less severe and less frequent after dosing. In the cohort
of 10 patients described by Chien et al, who were on average
younger than the subjects in our cohort, 6/10 subjects had gained
head control at 12 months, and 2/8 could sit independently after
2 years16. In the 6-subject cohort described by Kojima et al.17,
which included 4 subjects over age 10 years, none gained the
ability to sit independently at 2 years.
Diffuse restoration of AADC activity in dopamine terminals in
both the caudate nucleus and pre- and post-commissural puta-
men, as seen after midbrain administration of AAV2-hAADC in
our study, is likely to underlie the consistent improvement in
both motor and non-motor symptoms that we observed in our
subjects. We suspect that dopamine transmission in mesocortical
and mesolimbic pathways may also have improved, but detection
of AADC activity in anatomical regions such as the nucleus
accumbens and amygdala was unfortunately constrained by the
limits of PET resolution possible in this study.
HVA levels in the CSF constitute a direct biomarker of
dopamine metabolism. Low baseline levels of HVA represent
deficient activity of endogenous AADC and point to failure of
dopamine synthesis. Restoration of AADC in midbrain dopa-
minergic neurons leads to significant and consistent increases in
HVA concentration. We believe that restoration of this dopa-
minergic biomarker in the CSF is directly correlated with diffuse
and physiological activity of AADC in the dopaminergic brain
circuitry in AADC deficient children. We did observe a persistent
elevation of 3-OMD after gene delivery in all subjects, which is
consistent with some degree of residual AADC deficiency. The
marked clinical improvements we observed in our subjects
therefore did not require complete restoration of AADC function,
but the localization of that function, not only the extent, may be a
key determinant of clinical outcomes. Serotonergic brain circuitry
remained unaffected as demonstrated by lack of 5-HIAA increase
in the CSF since we restricted our gene delivery to the midbrain,
without any targeting of brain stem nuclei.
The durability of AADC transduction for children with AADC
deficiency is unclear, but clinical data from subjects with PD (>4
years) and pre-clinical data from non-human primates (>8
years)27–30 suggest that long-term and possibly life-long expres-
sion persists.
Gene therapy, i.e. gene replacement with functional genes, is a
potentially revolutionary therapeutic approach for many human
diseases. However, many technical hurdles exist for treatment of
complex diseases which include optimization of gene expression,
anatomic localization of gene expression, and availability of
appropriate endpoints to measure efficacy. From a technical
perspective, AADC deficiency has several favorable features. First,
gene replacement and expression in a specific small anatomic
area, midbrain dopaminergic neurons, has a large clinical impact.
This gene therapy clinical study is the first designed to pro-
spectively utilize axonal transport of viral vectors to disseminate
the therapeutic gene along brain circuitry affected by the gene
mutation. Second, the surgical and imaging tools currently
available, particularly MR-guided CED, permit highly accurate
delivery to virtually any region of the CNS with a favorable risk
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profile. And finally, direct imaging by FDOPA PET provides a
non-invasive tool to assess enzyme activity in the treated subjects.
Although this was an early phase clinical trial with safety as the
primary objective, the results obtained are consistent with suc-
cessful DDC gene delivery and expression in the human CNS. The
gene therapy approach described here represents many years of
careful work to develop and to understand vector tropism, axonal
transport, methods, and devices for gene delivery and application
of MRI technology to maximize safety and gene delivery. This
work provides a framework for the treatment of other human
CNS genetic diseases, and iterative refinement of the individual
components of this approach will facilitate broader application.
Methods
Study design. Our study complies with all ICMJE guidelines for reporting clinical
trials. This study was an adaptive, single-stage dose-escalation, open-label safety,
and efficacy study of AAV2-hAADC for the treatment of children with AADC
deficiency (ClinicalTrials.gov. identifier NCT02852213). The primary aims were to
demonstrate the safety of the procedure and document biomarker evidence of
restoration of brain AADC activity. Secondary aims were to assess clinical
improvement in symptoms and motor function.
Subjects were enrolled sequentially into two dose groups: 3 subjects in Cohort 1
(8.3 × 1011 vg/mL) followed by 4 subjects in Cohort 2 (2.6 × 1012 vg/mL). The total
infusate volume was 160 μL of vector for each subject. The vector concentration
was 3x higher for subjects in Cohort 2. We lowered the minimum age for inclusion
in the trial from 5 years to 4 years for Cohort 2 after demonstrating the safety of the
surgical procedure in Cohort 1. The minimum age criterion was in place to ensure
adequate skull maturity to tolerate the head fixation procedure required during
surgery.
Screening, treatment, and evaluation procedures were performed at UCSF
Benioff Children’s Hospital and The Ohio State University Wexner Medical
Center. Due to the ultra-rare nature of AADC deficiency a sample size of 7 subjects
was selected. Seven (7) subjects were treated with viral gene therapy according to
the study protocol. Subject 6 was the 6th subject to be screened for the study, but
was the final one (after Subject 7) to undergo surgery due to 2 severe respiratory
infections that delayed the scheduling of surgery following the initial
screening visit.
Written informed consent was obtained from the legally authorized
representative of all study participants. The study was reviewed and approved by
the Institutional Review Boards at the University of California San Francisco
(Protocol No. 15-17756, approved on 24 June 2016) and The Ohio State University
Wexner Medical Center (Protocol No. 2018H0269, approved on 29 November
2019). Videos containing identifying information are published with the consent of
each participant’s legally authorized representative.
Participants. Male and female subjects aged 4–9 years with a confirmed diagnosis
of AADC deficiency who met all inclusion/exclusion criteria were enrolled
(Enrollment dates - First participant: 2 December 2016; Last participant: 15
October 2018). Subjects were eligible if they had severe motor impairment (defined
as inability to walk, with or without an assistive device), despite treatment with
standard medical therapy for AADC deficiency. The main exclusion criteria were
medical co-morbidities judged to confer excessive surgical risk (such as baseline
requirement for home ventilatory support, structural brain malformation, and
coagulopathy), a history of previous stereotactic neurosurgery, and receipt of any
investigational agent within 60 days prior to Baseline and during study
participation.
Viral vector. The AAV2-hAADC vector consists of an adeno-associated virus,
serotype 2 (AAV2) containing human AADC complementary DNA (cDNA),
human cytomegalovirus (CMV) promoter, and 3′UTR sequences. AAV2-hAADC
was supplied in 0.5 mL aliquots as a suspension at a stock concentration of 4.9 ×
1012 vector genomes per mL. The vector and excipient for dilution were supplied to
the clinical site by the Clinical Vector Core, Children’s Hospital of Philadelphia.
Surgical procedure. The surgical procedure was performed in a 3T interventional
MRI suite. A combination of volumetric T1, slab T2, and slab inversion recovery
sequences were acquired prior to the procedure and bilateral VTA and SNc
infusion sites and trajectories were identified using standard software packages
(iPlan v3.0, Brainlab, Germany). The trajectories were designed to avoid cortical
veins and arteries, and the ventricular system. Following general anesthesia, the
subjects’ heads were immobilized with an MRI-compatible head-holder. A bicor-
onal scalp incision was made and two small craniotomies created in the right and
left frontal regions using the pre-selected entry points. The patient was then
transported to the intra-operative MR unit and skull-mounted aiming devices
(SmartFrame®, ClearPoint Neuro Inc. (formerly MRI Interventions Inc.)) were
mounted over each craniotomy site. The trajectory and depth were refined based
on intra-operative MR images acquired after placement of the targeting device. An
end-lumen ceramic and fused silica cannula with a progressive bullet-shaped step
design (ClearPoint Neuro Inc. (formerly MRI Interventions Inc.)) connected to an
infusion pump with a syringe was inserted into the SNc. The location of the
catheter was confirmed with a high-resolution MR scan prior to vector infusion.
Fifty microliters (50 µL) of the AAV2-hAADC vector and 2 mM of a chelated
gadolinium contrast agent (Gadoteridol (ProHance®, Bracco)) were infused into
the SNc by convection-enhanced delivery (CED), or pressurized infusion. The
catheter was withdrawn and repositioned using new target coordinates for the
VTA. This site was infused with 30 µL. A similar infusion protocol was repeated on
the opposite side. The total infusate volume was 160 μL of vector for each subject
(80 μL per hemisphere). Calculations were made of the total volume of infusate and
percentage of VTA and SN coverage by gadoteridol signal.
Outcome measures. Primary outcome measures assessed safety and biomarker
evidence of increased brain AADC activity. Safety of the procedure was evaluated by
brain MRI 48 h post-surgery, caregiver report of symptoms at each study visit,
neurologist rating of post-surgery involuntary movements (dyskinesia) at each study
visit, and caregiver diary of sleep and behavior symptoms at selected visits. Evidence
of biological AADC activity was measured by [18F]FDOPA PET and analysis of CSF
neurotransmitter metabolites before and after surgery. Secondary outcome measures
assessed clinical efficacy as expressed by improvements in symptoms and motor
function. Caregivers kept a detailed log of the duration and severity of all OGC (OGC
Log) before and after surgery. A checklist of AADC deficiency-related symptoms was
reviewed at each study visit. Caregivers periodically recorded sleep and behavior
observations in a 7-day diary. Gross motor function was evaluated using the Gross
Motor Function Measure-88 (GMFM-88). All measures are described in further detail
below, grouped by category (clinical/laboratory/imaging).
Clinical measures. A systematic assessment of adverse events and side effects was
performed at each visit with the study neurologist (Screening, Baseline, Weeks 1, 2,
4, 5, 6, 7, 8, and Months 3, 6, 12, 18, and 24). Information was recorded on an
Adverse Events (AE) Log which included type of AE, dates of onset and resolution,
severity, and perceived relationship to experimental therapy (Table 4). The severity
of each AE was rated based on the NCI Common Terminology Criteria for Adverse
Events v4.0 (CTCAE; https://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/CTCAE_4.03.xlsx). A general medical and a full
neurologic examination was conducted at each study visit with selected examina-
tions recorded on video.
At each study visit with the neurologist (see timepoints above), a standard
checklist of AADC deficiency-related symptoms was reviewed, in which parents
were asked to judge the severity of each symptom as “major” (frequent and/or
severe), “minor” (infrequent and/or mild), or absent. Subjects were also examined
by the neurologist at each visit to assess the severity of involuntary movements, or
dyskinesia. A dyskinesia score, based on the Abnormal Involuntary Movement
Scale (AIMS) was calculated by assessing the severity of involuntary movements in
each of 7 body regions on a scale of 0 (none) to 4 (severe), for a maximum possible
score of 28 (Fig. 5).
Caregivers documented the duration and severity of all OGC that occurred
during the study period, beginning 2 months prior to surgery, in an OGC Log.
OGCs typically occur 2–3 times per week and each episode lasts from 30min to 8
h; therefore, the average weekly duration and severity of episodes can be accurately
and reliably quantified. We created a 3-point scale to describe episode severity
based on clinical experience: Grade 1 (mild)= eye deviation only; Grade 2
(moderate)= eye deviation associated with involuntary facial movements; Grade 3
(severe)= eye deviation associated with dyskinesia or dystonia of the trunk and/or
limbs. Parents were trained at the initial screening visit to complete the OGC log by
documenting a start time, end time, and severity score (1–3) for each episode. They
then prospectively recorded all observed episodes throughout the study period. An
OGC severity score, consisting of a product of the duration (hours) and severity
(grade 1–3) was calculated by summing the number of hours of each severity
category per calendar month, and then calculating the weekly (7-day) average score
for that month. For example, a score of 15 may represent 5 h per week of severe
(severity score 3) symptoms, 15 h per week of mild (severity score 1) symptoms, or
an intermediate number of hours of symptoms of mixed severity.
A standardized behavior and sleep diary was used to capture sleep and mood
dysfunction resulting from brain dopamine dysregulation. Subject’s caregivers were
trained in the completion of a symptom diary by study center personnel. The
symptom diary was completed twice during the period between the Screening and
Baseline visits, each over a consecutive 7-day period at least 1 month apart. Follow-
up observations for 7-day periods were recorded at Week 6 and Months 3, 6, 12,
18, and 24 after surgery.
Gross motor function was evaluated using the GMFM-88. The total score was
derived as an unweighted average of the five dimension scores: lying and rolling (17
items); sitting (20 items); crawling and kneeling (14 items); standing (13 items) and
walking, running, and jumping (24 items). Each dimension score was defined as
percentage of maximum score for the dimension in question, and the maximum
possible total score was 100%. The evaluations were performed by a pediatric
physical therapist and recorded on video at Baseline, 3, 6 12, 18, and 24 months
after gene delivery. The assessments were then independently scored by two
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therapists, the one who had performed the test in-person, and a second therapist
who reviewed each recorded session on video (post-hoc, blinded to the timepoint
of each assessment). When the total scores of the two independent assessments
were within 2% points of each other, the score of the original (in-person) assessor
was retained. When there was a difference of >2 points between the total scores, a
third reviewer (TSP) reviewed the video to determine each individual item’s final
score and ensure accurate and consistent scoring across subjects.
The parents of all the patients participated in a formal survey interview using
the Vineland Adaptive Behavior Scale, Second Edition (VABS-II), a measure of
adaptive behavior and developmental functioning for individuals from birth
through 90 years of age31. This tool is administered to the primary caregiver of an
individual being assessed and provides information in various domains of
functioning. Specifically, there are four domains (Communication, Daily Living
Skills, Socialization, and Motor Skills), up to 11 subscales (three each for all
domains except Motor, which has two), and an overall Adaptive Behavior
Composite Score. Standard scores (population mean= 100, SD= 15) are produced
for the domain and composite scores, scaled scores (called v-scale scores, with a
population mean= 15, SD= 3) are produced for the subscale scores, age
equivalents can also be generated and may be combined to determine an overall
Adaptive Behavior Composite score. Strong internal consistency, test–retest
reliability, and validity have consistently been demonstrated. However, due to the
significant global developmental delays and limited abilities of our subject cohort,
there was no utility in calculating formal standard, scaled, and/or composite scores.
Instead, raw score comparisons were reviewed across time points to assess any
positive developmental progress (Supplementary Table 1). The VABS-II scale was
administered at Baseline, 12 and 24 months after surgery.
Laboratory analysis. CSF was collected by lumbar puncture with HPLC analysis of
the following metabolites: homovanillic acid (HVA), 5-hydroxyindoleacetic acid
(5-HIAA), 3-O-methyldopa (3-OMD), and 5-methyltetrahydrofolate (5-MTHF).
Plasma AADC enzyme activity was determined by quantitative HPLC method32,33.
Both analyses were performed by MNG Laboratories, a LabCorp Company
(Atlanta, GA).
Imaging studies. MR scans were performed pre-operatively as part of the screening
process, during the infusion procedure, and then at 48 h following the surgical
procedure, with a final scan obtained 24 months following the procedure. The 48-h
MR scan used a ‘rapid’ protocol and consisted of a 3D T2 FSE sequence, and axial
diffusion.
6-[18F]-fluoro-L-DOPA (FDOPA) is a PET radiopharmaceutical used to image
dopamine synthesis capacity. PET scans were performed at screening, and at
3 months, with a final study planned 24 months after the procedure. The pediatric
dose of 0.3 mCi for FDOPA was based on 10% of the adult dose of 3 mCi (UCSF
RUA approval: RU133031, OSU approval: 2018H0269). PET scans were analyzed
for quantification of AADC activity and differences in the distribution of AADC
activity between baseline and post-surgery scans.
[123I]ioflupane (DaTscan™) selectively binds to pre-synaptic dopamine
transporters and provides a method for imaging nigrostriatal terminals in the
striatum. DaTscan™ is a FDA-approved radiopharmaceutical used in conjunction
with single photon emission computed tomography (SPECT) scan for use in adults.
A DaTscan was performed at the screening visit to document nigrostriatal pathway
integrity.
Statistical analysis. Increases in CSF HVA from Baseline to Month 6 and Baseline
to Month 12 were analyzed using a one-tailed Wilcoxon signed-rank test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
De-identified individual participant data that underlie the results reported in this article
as well as the study protocol and analytic code will be shared beginning 3 months and
ending 5 years following article publication to researchers who provide a
methodologically sound proposal and only to achieve aims in the approved proposal.
Proposals should be directed to Krzysztof.Bankiewicz@osumc.edu. To gain access, data
requestors will need to sign a data access agreement. Source data are provided with
this paper.
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